enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update

Key Points

• enGene reported a promising efficacy signal for detalimogene in LEGEND cohort 1 with a 62% six‑month complete response, mostly grade 1–2 catheter‑related adverse events and low discontinuation rates, and expects a Q2 update on the primary "anytime CR" plus 12‑month durability data later in the year with a potential approval pathway toward 2027.
• CEO Ron Cooper emphasized that detalimogene is being designed as a community‑friendly NMIBC therapy—no special handling, standard refrigerator storage, exam‑room administration, and minimal in‑office time—to improve adoption among the ~83% of patients treated outside academic centers.
• Cooper framed the strategy around delaying radical cystectomy for a largely older, comorbid NMIBC population and positioned detalimogene’s logistical simplicity as a differentiator versus other newer agents and device approaches in a competitive, evolving treatment landscape.

enGene NASDAQ: ENGN Chief Executive Officer Ron Cooper used a presentation at the Citizens Life Sciences Conference to outline the company’s approach to non-muscle invasive bladder cancer (NMIBC), emphasizing both the unmet need in the disease and the company’s view that its investigational therapy, detalimogene, could be designed to fit more easily into community urology practices.

NMIBC treatment backdrop and the push to delay cystectomy

 

Cooper characterized the historical options for patients with NMIBC—often older men with comorbidities—as limited, pointing to BCG therapy followed by guideline-recommended radical cystectomy (bladder removal) after BCG failure. He described cystectomy as a major surgery with significant risks, citing a mortality rate of “5%–15%,” high morbidity, and quality-of-life impacts including ostomy use and loss of sexual function.

He argued that removing the bladder can be an extreme step for a disease he described as slow progressing, noting that NMIBC progresses at “20% over a 10-year timeframe.” Cooper said he is encouraged by the number of new agents entering the market, describing the situation as positive for patients and contributing to a “race” in development driven in part by FDA guidance that can support approvals from relatively small open-label studies in this setting.

Market split: academic centers vs. community practices

 

Cooper repeatedly highlighted the difference between academic and community settings, estimating that about 17% of patients are treated in academic centers while roughly 83% are treated in the community. He said that many newer products have had limited uptake in community urology because they are “clunky,” require special handling, lengthy thaw times, and can involve insurance complications.

As Cooper described it, community urologists today generally diagnose and treat patients with BCG and may use intravesical gemcitabine, but often refer patients to academic centers for additional options. In academic settings, he said patients may receive therapies such as Adstiladrin and Keytruda, followed by cystectomy. In the community, he cited ongoing constraints such as long-running BCG supply shortages and limited ability to integrate operationally complex therapies.

Detalimogene’s clinical update and what enGene is watching next

 

Discussing data from the company’s LEGEND study (cohort 1, which he described as the pivotal cohort), Cooper said enGene reported a six-month complete response (CR) rate of 62% in a data update last fall, calling it comparable to other agents in the category.

He placed particular emphasis on tolerability and treatment continuity. Cooper said most adverse events observed with detalimogene were grade 1 or 2 and associated with catheterization. He also pointed to low single-digit rates of discontinuations and treatment interruptions, contrasting that with other therapies that he said have higher rates, including figures “in the 40s or higher or in double digits.” To Cooper, those differences suggest patients are more likely to remain on schedule with therapy.

Looking ahead, Cooper said enGene expects to provide another data update at a spring conference in the second quarter, including final “anytime CR” rates, which he described as the primary endpoint. He said most of the 125 patients in the study will have passed the six-month time point by then. He also previewed an additional update in the second half of the year, when enGene expects to provide 12-month data, describing it as important for assessing longer-term durability.

Cooper said a filing would follow, with a potential approval in 2027. He also described how durability is assessed in the regulatory context, referencing duration of response (DOR) as a secondary endpoint and discussing 12-month “landmark” comparisons used in the space. While he said he expects immunotherapies to be durable and referenced a small nine-month snapshot from the prior update (five of five eligible patients reaching that mark), he cautioned the study is ongoing.

Operational focus: fitting into community urology workflows

 

Cooper framed detalimogene’s differentiation as being as much about logistics as clinical performance, arguing that community practices—often under staffing pressure and increasingly influenced by private equity ownership—need therapies that do not disrupt practice flow. He outlined several features he believes would reduce friction in community adoption:

• No special handling requirements, in contrast to certain virus-based products that can require decontamination procedures and additional precautions.
• Expected storage stability in a regular refrigerator for “many months” and in a freezer for “many years,” which he contrasted with “ultra cold chain” requirements for some therapies.
• No need for multiple pre-washes that can consume nursing time and resources.
• No need for a procedure room; he described administration as feasible in a standard exam room using typical catheter supplies.

 

Cooper also discussed time burdens for patients and clinics, suggesting that outside of clinical-trial urine collection requirements, the patient time in-office could be limited to “five or 10 minutes” for administration. He said the company may conduct pharmacoeconomic work over time to quantify potential benefits.

Competitive landscape comments and other LEGEND cohorts

 

Asked about competitor data (including Protara), Cooper said he viewed certain chemotherapy-oriented approaches as complementary rather than direct competitors, and suggested timelines and evolving FDA guidance could make it harder for late entrants to enroll the relevant third-line populations. He also mentioned Johnson & Johnson’s TAR-200 as part of the evolving community toolkit, while noting operational challenges such as time to place and remove devices and the need for repeat visits.

Finally, Cooper addressed other LEGEND cohorts—2A (BCG naïve), 2B (BCG exposed), and a papillary-only cohort without CIS—saying enGene had deprioritized those efforts while focusing on cohort 1 recruitment. He said cohort 1 ultimately over-enrolled by 25%, and noted that data from the additional cohorts could later help inform prescribing decisions, with papillary disease potentially relevant for NCCN guideline inclusion.

About enGene NASDAQ: ENGN

 

enGene is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

 

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.